Announced
Completed
Financials
Tags
Public
Merger
Single Bidder
Tender Offer
specialty pharmaceuticals
United States
Pharmaceuticals
Friendly
Majority
Completed
Synopsis
La Jolla Pharmaceutical, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, completed the acquisition of Tetraphase Pharmaceuticals, a biopharmaceutical company, for $43m and $16m potentially payable. “Combining with La Jolla, which markets GIAPREZA, the first new treatment for patients suffering from septic or other distributive shock in more than a decade, should help accelerate XERAVA’s availability to patients in need. We are excited to have the opportunity to combine with a company that has a strategic vision similar to our own,” Larry Edwards, Tetraphase President and Chief Executive Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.